NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Eagle, Agree. I see NWBO is becoming a BP platform company and creating an ecosystem to be a "dominant franchise".

1. Franchise = Proprietary Infrastructure
- Typical biotechs sell single drugs.
- NWBO’s owns proprietary DC therapy ecosystem, ie mfg IP, patents, and “blueprints” to scale.

2. Vertical Integration = Optimize gross margin %
- Typical biotechs outsource mfg to CMOs, losing 40–60% of margin
- NWBO owns the mfg / Advent (key), also enables continual process and cost-reduction improvements

3. Price Elasticity (“safety” advantage)
- Most BP drugs have a toxicity barrier, which limits drug label and addressable market
- DCVax-L’s vaccine-like safety and agnostic nature allows for a much larger market (multi-tumor)
- High gross margins from owning Advent gives NWBO the price elasticity to negotiate optimal pricing

4. Intellectual Property Moat
- In-licensing Roswell Park DC technology creates a “version 2.0” for the DCVax pipeline
- If 1.0 is priming the immune system, then 2.0 is reprogramming the Tumor Microenvironment TME, to turn “cold” tumors “hot”.

5. Franchise as Strategic Footprint
- As base-layer treatment or for combos like DCVax + Keytruda or DCVax + Poly-ICLC (similar to the Merck model)
- The “Sawston Model” is a repeatable, proprietary, standardized system. NWBO can “copy-paste” these internal hubs around the world.